Breakthrough in understanding common childhood cancer

November 25, 2019

Scientists studying one of the most common forms of childhood cancer have made an important breakthrough in understanding how the disease progresses.

Neuroblastoma is a rare type of cancer of the nervous system that mainly affects babies and young children.

It often begins in the adrenal gland but in around half of cases the condition has spread throughout the body when it is diagnosed, particularly to bone and bone marrow, and in these high risk cases survival is only about 50%.

A study, led by experts at Newcastle University, UK, and published today in Clinical Cancer Research, has focussed on neuroblastoma cells which circulate in the blood and spread through the bone marrow.

It is the first time that circulating neuroblastoma tumour cells have been identified in this way and experts say it is possible to test the effect of newer targeted types of treatments on the circulating tumour cells without the need for an invasive biopsy.

Understanding the disease

Professor Deborah Tweddle, from the newly-formed Newcastle University Centre for Cancer, led the national study and believes that it is a major step forward in trying to personalise treatment as the number of circulating tumour cells indicate the strength of the disease.

She said: "Our study is an exciting development. It has improved our understanding of the spread of neuroblastoma and why some young patients may be at high risk of the disease advancing.

"If the numbers of circulating tumour cells prove important in predicting the effects of chemotherapy then, in the future, we will hopefully be able to tailor treatment to an individual patient's needs.

"Through a greater understanding of neuroblastoma we hope to eventually improve the cure rate and, for those children who survive, we want to make sure that their quality of life is as good as possible after treatment.

"Our ultimate aim is to give those with this devastating disease the best chance possible and increase survival rates."

This study is an example of the pioneering research that is taking place at Newcastle University Centre for Cancer, with a focus on the 'discovery to trial to healthcare pathway'.

Scientists collected blood and bone marrow samples from patients at five paediatric oncology centres in England and Scotland. A total of 40 patients were studied, 23 had high risk neuroblastoma at diagnosis.

The team analysed the samples using specialist equipment - an Image Stream Flow Cytometer run by Dr David Jamieson - to count the number of tumour cells circulating in the blood and bone marrow by labelling the tumour cells with an antibody against a molecule called GD2 present on neuroblastoma cells and photographing them. Anti-GD2 antibody therapy is now routinely used for treatment of patients with high risk neuroblastoma.

Experts also collected the plasma of the blood after the cells were removed and found that they could still detect small pieces of tumour DNA. Genetic tests were carried out on the DNA and it was identified that they were similar to that of the main tumour.

Professor Tweddle, an Honorary Consultant in Paediatric Oncology at the Great North Children's Hospital, Newcastle, said: "To our knowledge, this is the first study in the world to use this type of specialist equipment to look for circulating tumour cells in neuroblastoma.

"Clearly it is early days, but this study is promising as it means that we can look at tumour cells as well as tumour DNA from the same blood sample. Therefore, if it's too hazardous to biopsy the main tumour we can get all the important genetic information we need from a blood test."

Further research will look at a much larger number of patients and will be done as part of the next European high risk neuroblastoma trial, which is hoped will be open in the UK next year.

Patient's perspective

Gemma Lowery sadly knows first-hand the devastation that neuroblastoma can cause.

Her inspirational son, Bradley, died at the age of six after bravely battling the illness from being a toddler. When it was revealed that the condition was terminal, Bradley appeared as mascot for his beloved Sunderland AFC and struck up a close bond with striker Jermain Defoe.

Gemma, of Blackhall Colliery, County Durham, has welcomed the Newcastle University research as she says it is key that there is a better understanding into the development of the condition.

She said: "It is extremely important that as much research as possible is done into neuroblastoma to help improve treatments for children with the condition.

"In general, not enough research is done into childhood cancer so the fact that Newcastle University is leading the way in studying neuroblastoma is fantastic.

"It's great that this research is a stepping stone towards personalised treatment as the standard treatment currently given is gruelling. Bradley was on life-support for 15 days, not from the cancer but from the effects of the chemotherapy.

"The Bradley Lowery Foundation is pushing for more people to become involved in scientific research and this is an example of the importance of it."
-end-
Information about the Bradley Lowery Foundation Research Fund can be found here: http://bit.ly/BLFresearch

Reference

Detection of circulating and disseminated neuroblastoma cells using the Imagestream Flow Cytometer for use as predictive and pharmacodynamic biomarkers

Swathi Merugu et al.

Clinical Cancer Research.

Newcastle University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.